Using an HK1−HK2+ subpopulation of liver cancers as an example, we developed a synergistic combination of HK2 inhibition and partial inhibition of mitochondrial complex I and fatty acid oxidation to achieve synthetic lethality of these HK1−HK2+ tumors. Here, HK2 is linked to liver cancer.